Clinical trial
Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia
NCT00005937 · Neal Young, M.D., NIH · Completed
Key facts
| NCT number | NCT00005937 |
|---|---|
| Title | Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia |
| Official title | A Phase II Study of Antithymocyte Globulin (ATG) and Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Neal Young, M.D., NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | Antithymocyte globulin, Cyclosporine |
| Enrollment | 42 |
| Start date | Jun 1, 2000 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jul 7, 2000 |
| Last update posted | Oct 23, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: